Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Jain, N., Kirby, S., Liedtke, M., Litzow, M., Logan, A., Luger, S., Maness, L. J., Massaro, S., Mattison, R. J., May, W., Oluwole, O., Park, J., Przespolewski, A., Rangaraju, S., Rubnitz, J. E., Uy, G. L., Vusirikala, M., Wieduwilt, M., Lynn, B., Berardi, R. A., Freedman-Cass, D. A., Campbell, M. 2021; 19 (9): 1079-1109

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

View details for DOI 10.6004/jnccn.2021.0042

View details for PubMedID 34551384